Amphastar Pharmaceuticals (AMPH) Income from Non-Controlling Interests (2018 - 2021)

Amphastar Pharmaceuticals' Income from Non-Controlling Interests history runs 4 years deep, the most recent figure standing at $1.4 million for Q3 2021.

• On a quarterly basis, Income from Non-Controlling Interests rose 61.56% year-over-year to $1.4 million in Q3 2021; TTM through Dec 2021 was $1.6 million, a 45.66% decrease from a year earlier, with the FY2021 full-year figure at $1.2 million, up 487.25% from the prior year.
• Income from Non-Controlling Interests grew to $1.4 million in Q3 2021 per AMPH's latest filing, from -$855000.0 in the prior quarter.
• Across five years, Income from Non-Controlling Interests topped out at $6.6 million in Q4 2019 and bottomed at -$855000.0 in Q2 2021.
• The 4-year median for Income from Non-Controlling Interests is $867000.0 (2019), against an average of $1.1 million.
• Across the five-year window, Income from Non-Controlling Interests soared 4562.42% in 2019 and slumped 169.12% in 2021, its largest moves.
• Year by year, Income from Non-Controlling Interests stood at -$149000.0 in 2018, then surged by 4562.42% to $6.6 million in 2019, then slumped by 92.77% to $481000.0 in 2020, then soared by 193.56% to $1.4 million in 2021.
• Per Business Quant, the three latest AMPH Income from Non-Controlling Interests figures stand at $1.4 million (Q3 2021), -$855000.0 (Q2 2021), and $1.1 million (Q1 2021).